Brief: Anti-Cancer Potential Of Rencofilstat Expanded With Results From Preclinical Multiple Myeloma Studies
18/01/2023 14:35
Jan 18 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* ANTI-CANCER POTENTIAL OF RENCOFILSTAT EXPANDED WITH
RESULTS FROM
PRECLINICAL MULTIPLE MYELOMA STUDIES
* HEPION PHARMACEUTICALS INC - SYNERGISTIC ACTIVITY
DEMONSTRATED
WITH RENCOFILSTAT IN COMBINATION WITH FIRST LINE MULTIPLE
MYELOMA DRUG, BORTEZOMIB
* HEPION PHARMACEUTICALS INC - ANNOUNCED POSITIVE RESULTS OF
PRECLINICAL STUDIES EXAMINING RENCOFILSTAT AS A POTENTIAL
THERAPEUTIC FOR MULTIPLE MYELOMA
Source text for Eikon: ID:nGNX8J01NQ
Further company coverage: HEPA.O
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement